Jagsonpal Pharmaceuticals Ltd. acquires Wellness Portfolio of Group Pharmaceuticals, enhancing its pharmaceutical portfolio and market reach.
Jagsonpal Pharmaceuticals Ltd reports Q1 FY27 results with revenue up 9% and PAT up 22%, maintaining robust cash reserves at ₹1,700 Mn.
Jagsonpal Pharmaceuticals to acquire 85% stake in Aequitas Healthcare, marking strategic entry into hospital segment.
Jagsonpal Pharmaceuticals Limited (JAGSNPHARM) announces the appointment of industry veteran Anil Kumar Matai as an Independent Director, effective June 25.